To improve upon the non-invasive detection of bladder cancer by further validating a
multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in
voided urine samples of patients with a high risk of developing bladder cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT05347342.
Locations matching your search criteria
United States
California
Los Angeles
Cedars Sinai Medical CenterStatus: Active
Contact: Hideki Furuya
Phone: 310-423-4607
Environmental exposures, specifically tobacco smoke, increases the risk of many cancers,
including bladder cancer. To date, there are no diagnostics capable of detecting bladder
cancer early, that is prior to clinical presentation. Because of this severe limitation,
nearly 30% of patients initially present with stage 2 and higher bladder cancer. Stage 2
bladder cancer has a 5-year survival of 50%, while stage 3/4 have a 5-year survival of
<20%. Ideally, bladder cancer would be preventable. Unfortunate, this has not come to
fruition. If these stage 2-4 bladder cancer cases could be detected at Stage 1 (5-yr
survival >94%), then its possible to see an improvement in bladder cancer survival rates
(21-23).
in this study, a urine-based diagnostic that possesses the potential to accurately
identify patients who harbor bladder cancer prior to clinical manifestation will be
tested.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationCedars Sinai Medical Center
Principal InvestigatorHideki Furuya